W. Tim Miller, MBA, President and CEO
Mr. Miller is an experienced CEO, has been with Echelon 5 years and has 30 years of practice building successful teams in public and private companies. Recent successes include the building and strategic exit of a bio-pharma company and an IPO for a trans-dermal drug delivery company. With a successful history in strategic planning, operations, business development, and funding, his drug/device experience includes Marion Laboratories, American Home Products Corporation, American Hospital Supply Corporation, William H. Rorer, and Iomed, Inc. His M.B.A. is from the University of Utah where he graduated first in his class with honors. For two consecutive years, he has been recognized as one of Utah?s top 100 venture entrepreneurs and is an Adjunct Professor of Business at the University of Utah. He helped establish Angel Flight (www.angelflight.org) in Utah in 1999.
Kelly Sauder is the accounting manager of Echelon Biosciences, Inc, with responsibilities in both accounting and human resources. She has obtained bachelor of science degrees in accounting and business economics. She has 5 years experience in public accounting and auditing, 2 years experience in the private business sector, and is currently pursuing CPA certification.
Paul Neilsen, Ph.D., Director of R&D and Manufacturing
Dr. Neilsen has a BS in biochemistry from Brigham Young University and a Ph.D. with honors in Experimental Pathology from the University of Utah. Primary or contributing author for 8-10 peer-reviewed scientific papers including Journal of Biological Chemistry, Nature Cell Biology, and Journal of Immunology. He is an Adjunct Professor of Biology at Salt Lake Community College.
Dr. Ferguson has a B.S. with honors in Chemistry and Oceanography, University of British Columbia, Vancouver; a Ph.D. in Chemistry, Queens University, Kingston, Ontario, Canada; and a Postdoctoral Fellow, Medicinal Chemistry, University of Utah. His knowledge of phosphoinositide syntheses allows Echelon to expand its product offerings and constantly improve its operational efficiencies.
Charles (Chad) Testa, Ph.D., Director of Anti-infective Development
Dr. Charles Testa has spent the previous 10 years studying isoprenoid biosynthesis, with the majority being focused on the MEP pathway. He has a B.A. in Biochemistry from Ithaca College, an M.S. from Bucknell University and a Ph.D. in Chemistry from the University of Utah. Dr. Testa has been at Echelon for 5 years where he has progressed from Research Scientist to Project Manager to Director of Anti-infective Drug Development.
James Thompson, MSc, Director of New Product Development
James has 9 years of industry experience in the biological sciences serving as Director of R&D and Executive Director of the Spendlove Research Foundation, co-founder Quansys Biosciences, and Director of New Product Development at Echelon Biosciences. Member of the American Society for Cell Biology, American Society for Microbiology, and an associate member of the American Association for Cancer Research. A.S. in biology at Brigham Young University ? Idaho; B.S. and M.S. in biology at Utah State University. James is an Adjunct Professor of Biology at Salt Lake Community College.